The company, spun out of David Liu's laboratory, is developing small-molecule therapeutics that target exosites. Its core approach focuses on small molecules designed to engage exosites on target proteins. The startup has raised a modest $25M to push its programs toward clinical testing. The funding is described as intended to advance the company toward the clinic. David Liu is noted in the article as a CRISPR pioneer behind Editas Medicine, Beam Therapeutics and Prime Medicine. Genalyte is a San Diego-based life sciences company developing and commercializing innovative next-generation multiplexing technology. The article describes the company's core product focus solely as 'next-generation multiplexing technology' and provides no further product details. Genalyte announced completion of a Series B financing totaling $11.8 million. The article's headline rounds that figure to $12M, while the body reports $11.8M. No investors, financing instruments beyond 'Series B', operating metrics, past rounds, or founding year are disclosed in the article. The announcement was published by Massinvestor, Inc.

Total raised

$37M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2020